News 5 March, 2024Brisbane startup Infensa spins medical miracle from spider venom 14 December, 2023Infensa scientists publish paper in the European Heart Journal establishing efficacy of lead drug candidate when administered at clinically relevant timepoints in preclinical models of moderate and severe myocardial infarction 17 November, 2023Infensa CEO Associate Professor Mark Smythe received the LSQ McCullough Robertson Industry Excellence Award from Life Sciences Queensland in recognition of his major contributions to the Queensland life sciences industry 16 October, 2023Infensa CSO and co-founder Professor Glenn King received the Prime Minster’s Prize for Innovation, the highest honour for science translation in Australia 7 July, 2022The Translational Research Institute welcomes new startup Infensa Bioscience 4 July, 2022Australian Financial Review: Aussie start-up using funnel web venom to save lives scores $23 million 29 July, 2021Fraser Island funnel web spider venom shows promise for heart-attack treatment 20 July, 2021Deadly spider’s venom could someday help heart attack victims, Australian scientists say 16 July, 2021Deadly venom from funnel-web spider found only in Queensland could contain life-saving heart attack treatment 16 July, 2021Death disruptor: how an Australian funnel-web spider may help human hearts 16 July, 2021One of the world's deadliest spider venoms could help heart attack patients 16 July, 2021Aussie scientists see life-saving potential in spider venom 16 July, 2021Stopping 'death signal': Scientists look to repair hearts using deadly spider venom 23 May, 2024Infensa CSO and co-founder Professor Glenn King elected a Fellow of the Australian Academy of Science 15 July, 2021Infensa scientists publish key paper in Circulation showing efficacy of lead drug candidate in preclinical models of myocardial infarction and heart transplantation 30 July, 2024Infensa Bioscience selected as a finalist for the 2024 KE Select Emerging Innovator Award by Life Sciences Queensland
